Page 119 - Haematologica July

potential novel targets.14-17 Recently, four new-generation drugs have been approved in the USA in refractory/relapsed TCL: pralatrexate (antifolate), romidepsin and belinostat (histone deacetylase inhibitor), and brentuximab vedotin. In addition to these approved drugs, a number of novel drugs with different mechanisms are under investigation: crizotinib (oral tyrosine kinase inhibitor of ALK), mogamulizumab, duvelisib, plitidepsin, and selinexor.9,18 Hopefully, these agents will have an impact both when combined with front-line chemothera- py as well as in the relapsed and refractory setting.
Although the patient cohort could be not completely homogeneous (Investigators were requested to register consecutive cases satisfying the inclusion criteria without selection), the amplitude of the TCP reflects the real- world scenario, obtained through a multi-national data- base describing the distribution of PTCL subtypes and therapeutic outcomes with standard therapies. Our results complement those of the COMPLETE registry (clinicaltrials.gov identifier: 01110733), a similar prospective
study of PTCL patients in the US. These results will pro- vide a useful baseline on which to assess the efficacy of novel agents and therapies for refractory/relapsed patients with T-cell lymphomas. Clinical trials are under- way exploring the activity of novel agents in combination with chemotherapy to improve overall response in the front line, and single agent and combination studies of novel agents are underway for patients with refractory/relapsed disease.
Acknowledgments
For supporting this study, the authors would like to thank the Fondazione Cassa di Risparmio di Modena, Modena, Italy, the Associazione Angela Serra per la Ricerca sul Cancro, Modena, Italy, the Fondazione Italiana Linfomi (FIL), Alessandria, Italy, Allos Therapeutics, Inc., Westminster, CO, USA, and Spectrum Pharmaceuticals Inc., Henderson, NV, USA, AIRC (Associazione Italiana per la Ricerca sul Cancro) 5x1000 (grant n. 10007 to Stefano Pileri), the NIH/NCI CCSG P30 CA008748 (grant to Steven Horwitz).
References
1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
3. AdamsSV,NewcombPA,ShustovAR.Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol. 2016;34(9):963-971.
4. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classifica- tion confirms the clinical relevance of immunophenotype in 560 cases of aggres- sive non-Hodgkin’s lymphoma. Blood. 1997;89(12):4514-4520.
5. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial fea- tures, natural history, and prognostic fac- tors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9(8):849-855.
6. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas.
Groupe d’Etudes des Lymphomes de
l’Adulte (GELA). Blood. 1998;92(1):76-82.
7. Mak V, Hamm J, Chhanabhai M, et al. Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. J Clin Oncol.
2013;31(16):1970-1976.
8. Biasoli I, Cesaretti M, Bellei M, et al.
Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. Hematol Oncol. 2015;33(3):147-151.
9. Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99214-227.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues: Pathology and Genetics. Lyon, France: IARC Press; 2001.
11. Federico M, Bellei M, Pesce E, et al. T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. Rev Bras Hematol Hemoter. 2009;31(2):21-25.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to
standardize response criteria for non- Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
13. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lym- phoma. J Clin Oncol. 2007;25(5):579-586.
14. Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T- cell lymphomas: results of a phase III diag- nostic accuracy study. J Clin Oncol. 2013;31(24):3019-3025.
15. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T- cell lymphoma. Blood. 2014;123(19):2915- 2923.
16. O’Connor OA, Bhagat G, Ganapathi K, et al. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clin Cancer Res. 2014;20(20):5240-5254.
17. Inghirami G, Chan WC, Pileri S. Peripheral T-cell and NK cell lymphoproliferative dis- orders: Cell of origin, clinical and patholog- ical implications. Immunol Rev 2015;263 (1):124–159.
18. Coiffier B, Federico M, Caballero D, et al. Therapeutic options in relapsed or refracto- ry peripheral T-cell lymphoma. Cancer Treat Rev. 2014;40(9):1080-1088.
haematologica | 2018; 103(7)
Dismal outcome of refractory/relapsed PTCL
1197